Will Novo’s LEADER Trial Move GLP-1 To The Front Line In High-Risk Diabetes?

Novo Nordisk sets its sights on GLP-1 expansion after Victoza scores in CV outcomes trial, but docs want the full dataset to understand the robustness and implications of results.